Who are Oral Maalox/ Mylanta's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Alka Seltzer Extra Strength, Sodium Bicarbonate and Sodium chloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-maalox-mylanta.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Oral Maalox/ Mylanta — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral Maalox/ Mylanta (Oral Maalox/ Mylanta) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antacid combination. Area: Gastroenterology.

marketed Antacid combination Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Oral Maalox/ Mylanta (Oral Maalox/ Mylanta) — Stony Brook University. Maalox/Mylanta neutralizes gastric acid and reduces acid reflux symptoms through a combination of aluminum hydroxide, magnesium hydroxide, and simethicone.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Oral Maalox/ Mylanta TARGET	Oral Maalox/ Mylanta	Stony Brook University	marketed	Antacid combination
Alka Seltzer Extra Strength	Alka Seltzer Extra Strength	Bayer	marketed	Antacid combination with analgesic	Cyclooxygenase (COX) enzymes; gastric acid neutralization
Sodium Bicarbonate and Sodium chloride	Sodium Bicarbonate and Sodium chloride	University Hospital, Clermont-Ferrand	marketed	Electrolyte and antacid combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antacid combination class)

Stony Brook University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral Maalox/ Mylanta — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-maalox-mylanta. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab